A Phase II Trial of The Oral Mtor Inhibitor Everolimus in Relapsed Hodgkin Lymphoma

PURPOSE: Everolimus is an oral antineoplastic agent that targets the raptor mammalian target of rapamycin (mTORC1). The phosphatidylinositol 3-kinase/mTOR signal transduction pathway has been demonstrated to be activated in tumor samples from patients with Hodgkin Lymphoma (HL). The goal of this tri...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Am J Hematol
Auteurs principaux: Johnston, Patrick B., Inwards, David J., Colgan, Joseph P., LaPlant, Betsy R., Kabat, Brian F., Habermann, Thomas M., Micallef, Ivana N., Porrata, Luis F., Ansell, Stephen M., Reeder, Craig B., Roy, Vivek, Witzig, Thomas E.
Format: Artigo
Langue:Inglês
Publié: 2010
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4420736/
https://ncbi.nlm.nih.gov/pubmed/20229590
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.21664
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires